Jonathan Eric Leeman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 18 | 2024 | 1330 | 5.060 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2021 | 798 | 2.350 |
Why?
|
Prostatic Neoplasms | 17 | 2024 | 11094 | 1.540 |
Why?
|
Neoplasms, Second Primary | 4 | 2023 | 1062 | 1.100 |
Why?
|
Head and Neck Neoplasms | 11 | 2019 | 2930 | 1.090 |
Why?
|
Skull Base Neoplasms | 2 | 2018 | 280 | 0.910 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3186 | 0.880 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 11 | 2024 | 1673 | 0.860 |
Why?
|
Papillomavirus E7 Proteins | 2 | 2021 | 109 | 0.850 |
Why?
|
Oropharyngeal Neoplasms | 3 | 2017 | 492 | 0.820 |
Why?
|
Radiation Injuries | 4 | 2023 | 1195 | 0.810 |
Why?
|
Kidney Neoplasms | 3 | 2023 | 4282 | 0.790 |
Why?
|
Radiotherapy Dosage | 11 | 2024 | 2916 | 0.670 |
Why?
|
Prostatectomy | 6 | 2024 | 1785 | 0.670 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 93 | 0.620 |
Why?
|
Brachytherapy | 3 | 2021 | 1221 | 0.610 |
Why?
|
Coronavirus | 1 | 2020 | 155 | 0.600 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 268 | 0.580 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2017 | 289 | 0.570 |
Why?
|
Radiotherapy, Conformal | 2 | 2019 | 545 | 0.560 |
Why?
|
September 11 Terrorist Attacks | 1 | 2018 | 107 | 0.560 |
Why?
|
Carcinoma | 2 | 2018 | 2325 | 0.520 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2017 | 243 | 0.480 |
Why?
|
Immunomodulation | 1 | 2019 | 548 | 0.480 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2023 | 9407 | 0.470 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1203 | 0.470 |
Why?
|
Prostate | 5 | 2024 | 1760 | 0.410 |
Why?
|
Spinal Neoplasms | 2 | 2016 | 714 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2021 | 4050 | 0.400 |
Why?
|
Androgen Antagonists | 4 | 2024 | 1411 | 0.400 |
Why?
|
Microbubbles | 4 | 2013 | 137 | 0.370 |
Why?
|
Prostate-Specific Antigen | 5 | 2024 | 2463 | 0.370 |
Why?
|
Ultrasonic Therapy | 1 | 2012 | 216 | 0.350 |
Why?
|
Brain Stem Neoplasms | 1 | 2012 | 191 | 0.340 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2023 | 3681 | 0.340 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11218 | 0.330 |
Why?
|
Brain Edema | 1 | 2013 | 601 | 0.320 |
Why?
|
Endoscopy | 1 | 2018 | 1854 | 0.300 |
Why?
|
Tumor Burden | 4 | 2024 | 1902 | 0.300 |
Why?
|
Sarcoma | 2 | 2016 | 1802 | 0.290 |
Why?
|
Neurosurgical Procedures | 1 | 2018 | 2077 | 0.280 |
Why?
|
Misonidazole | 2 | 2017 | 33 | 0.280 |
Why?
|
Male | 44 | 2024 | 364154 | 0.250 |
Why?
|
Prospective Studies | 11 | 2024 | 54872 | 0.250 |
Why?
|
Thromboembolism | 1 | 2012 | 1003 | 0.250 |
Why?
|
Humans | 61 | 2024 | 766812 | 0.250 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5444 | 0.240 |
Why?
|
Lung Neoplasms | 5 | 2024 | 13489 | 0.240 |
Why?
|
Lymphatic Metastasis | 3 | 2017 | 2901 | 0.240 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2023 | 1788 | 0.220 |
Why?
|
Lung | 3 | 2024 | 10068 | 0.220 |
Why?
|
Urogenital System | 1 | 2023 | 88 | 0.220 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6359 | 0.220 |
Why?
|
Thrombolytic Therapy | 1 | 2012 | 2053 | 0.210 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2024 | 140 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3110 | 0.210 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 2 | 2013 | 43 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3232 | 0.200 |
Why?
|
Neoplasms | 4 | 2021 | 22350 | 0.200 |
Why?
|
Papillomavirus Infections | 4 | 2021 | 1639 | 0.200 |
Why?
|
Kaplan-Meier Estimate | 6 | 2019 | 6514 | 0.200 |
Why?
|
Middle Aged | 31 | 2024 | 223267 | 0.200 |
Why?
|
Aged | 29 | 2024 | 171344 | 0.190 |
Why?
|
Aged, 80 and over | 16 | 2020 | 59548 | 0.190 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 269 | 0.190 |
Why?
|
Propensity Score | 2 | 2021 | 1972 | 0.180 |
Why?
|
Retrospective Studies | 20 | 2024 | 81657 | 0.180 |
Why?
|
Magnetic Resonance Imaging | 10 | 2024 | 36570 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8734 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11876 | 0.170 |
Why?
|
Radiometry | 3 | 2020 | 814 | 0.170 |
Why?
|
Oncogene Proteins, Viral | 1 | 2021 | 342 | 0.170 |
Why?
|
Radiation Pneumonitis | 1 | 2020 | 100 | 0.170 |
Why?
|
Papillomaviridae | 4 | 2021 | 1139 | 0.170 |
Why?
|
Organs at Risk | 2 | 2024 | 367 | 0.170 |
Why?
|
Probability | 2 | 2022 | 2476 | 0.160 |
Why?
|
Urethra | 1 | 2021 | 406 | 0.160 |
Why?
|
Breast Neoplasms | 2 | 2023 | 21162 | 0.160 |
Why?
|
Jaw | 1 | 2019 | 95 | 0.160 |
Why?
|
Tonsillar Neoplasms | 1 | 2019 | 49 | 0.160 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2019 | 877 | 0.160 |
Why?
|
Follow-Up Studies | 10 | 2019 | 39312 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 219 | 0.160 |
Why?
|
Prognosis | 10 | 2024 | 29959 | 0.160 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2021 | 605 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 514 | 0.150 |
Why?
|
Disease-Free Survival | 5 | 2019 | 6853 | 0.140 |
Why?
|
Larynx | 1 | 2022 | 492 | 0.140 |
Why?
|
Oxygen Consumption | 1 | 2023 | 1874 | 0.140 |
Why?
|
Fatigue | 1 | 2023 | 1555 | 0.130 |
Why?
|
Fanconi Anemia | 1 | 2019 | 327 | 0.130 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2902 | 0.130 |
Why?
|
Hemangiopericytoma | 1 | 2016 | 71 | 0.130 |
Why?
|
Brain Neoplasms | 2 | 2015 | 9101 | 0.130 |
Why?
|
Radium | 1 | 2016 | 70 | 0.130 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12536 | 0.120 |
Why?
|
Female | 28 | 2024 | 396532 | 0.120 |
Why?
|
Epithelium | 1 | 2019 | 1606 | 0.120 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 705 | 0.110 |
Why?
|
Thyroidectomy | 1 | 2019 | 912 | 0.110 |
Why?
|
Pilot Projects | 2 | 2024 | 8728 | 0.110 |
Why?
|
Radiation Dosage | 1 | 2021 | 1958 | 0.100 |
Why?
|
Mouth Neoplasms | 1 | 2018 | 597 | 0.100 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2662 | 0.100 |
Why?
|
Disease Progression | 4 | 2017 | 13642 | 0.100 |
Why?
|
Survival Rate | 6 | 2020 | 12826 | 0.100 |
Why?
|
Adult | 19 | 2020 | 223305 | 0.100 |
Why?
|
Treatment Outcome | 13 | 2019 | 65286 | 0.100 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6066 | 0.100 |
Why?
|
Deglutition Disorders | 1 | 2017 | 640 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2018 | 1274 | 0.090 |
Why?
|
Myocardial Infarction | 1 | 2012 | 11514 | 0.090 |
Why?
|
Treatment Failure | 1 | 2017 | 2659 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3942 | 0.090 |
Why?
|
Stents | 1 | 2023 | 3193 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5389 | 0.090 |
Why?
|
Blood Cells | 1 | 2012 | 309 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3989 | 0.090 |
Why?
|
Ultrasonics | 1 | 2011 | 208 | 0.080 |
Why?
|
Necrosis | 1 | 2013 | 1614 | 0.080 |
Why?
|
Cell Line | 2 | 2021 | 15564 | 0.080 |
Why?
|
Tomography, Optical Coherence | 2 | 2012 | 2954 | 0.080 |
Why?
|
Time Factors | 4 | 2019 | 40149 | 0.080 |
Why?
|
Databases, Factual | 3 | 2019 | 8065 | 0.070 |
Why?
|
Knee Injuries | 1 | 2013 | 495 | 0.070 |
Why?
|
Palliative Care | 1 | 2023 | 3640 | 0.070 |
Why?
|
Kidney | 1 | 2023 | 7073 | 0.070 |
Why?
|
Risk Assessment | 5 | 2020 | 24299 | 0.070 |
Why?
|
Genomics | 2 | 2021 | 5922 | 0.070 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2631 | 0.070 |
Why?
|
Tissue Plasminogen Activator | 1 | 2012 | 1164 | 0.070 |
Why?
|
Blood Coagulation | 1 | 2012 | 1163 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2355 | 0.060 |
Why?
|
Linear Models | 1 | 2016 | 5873 | 0.060 |
Why?
|
DNA | 1 | 2019 | 7210 | 0.060 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2011 | 504 | 0.060 |
Why?
|
Swine | 2 | 2013 | 5985 | 0.060 |
Why?
|
Aortic Diseases | 1 | 2011 | 741 | 0.060 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2809 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3468 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6779 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13276 | 0.060 |
Why?
|
Knee Joint | 1 | 2013 | 1682 | 0.060 |
Why?
|
Equipment Design | 1 | 2012 | 3488 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12064 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2012 | 6214 | 0.050 |
Why?
|
Aorta | 1 | 2011 | 2043 | 0.050 |
Why?
|
Contrast Media | 2 | 2016 | 5329 | 0.050 |
Why?
|
Image Enhancement | 1 | 2013 | 2858 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8045 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2012 | 2078 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18397 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22248 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8352 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 172 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6548 | 0.040 |
Why?
|
Mesenchymal Stem Cells | 1 | 2011 | 1664 | 0.040 |
Why?
|
Thrombosis | 1 | 2013 | 2953 | 0.040 |
Why?
|
Observer Variation | 2 | 2017 | 2614 | 0.040 |
Why?
|
Stromal Cells | 1 | 2024 | 1334 | 0.040 |
Why?
|
Young Adult | 4 | 2019 | 59939 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20146 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12985 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2021 | 670 | 0.040 |
Why?
|
Indazoles | 1 | 2019 | 306 | 0.040 |
Why?
|
Pelvis | 1 | 2022 | 737 | 0.040 |
Why?
|
Neck Dissection | 1 | 2019 | 201 | 0.040 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2021 | 802 | 0.030 |
Why?
|
Epidural Neoplasms | 1 | 2016 | 24 | 0.030 |
Why?
|
Androgens | 1 | 2024 | 1280 | 0.030 |
Why?
|
Liposarcoma, Myxoid | 1 | 2016 | 60 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10101 | 0.030 |
Why?
|
Thoracotomy | 1 | 1997 | 374 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2017 | 193 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2144 | 0.030 |
Why?
|
Mastectomy | 1 | 2023 | 1861 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2021 | 1155 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2441 | 0.030 |
Why?
|
DNA, Viral | 1 | 2021 | 2201 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1444 | 0.030 |
Why?
|
Morbidity | 1 | 2019 | 1754 | 0.030 |
Why?
|
Fibrosarcoma | 1 | 2016 | 313 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2495 | 0.030 |
Why?
|
Emergency Treatment | 1 | 1997 | 495 | 0.030 |
Why?
|
Transfection | 1 | 2021 | 5755 | 0.030 |
Why?
|
Cell Cycle | 1 | 2021 | 2925 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2022 | 2474 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2017 | 2275 | 0.030 |
Why?
|
Rhabdomyosarcoma | 1 | 2016 | 358 | 0.030 |
Why?
|
Motion | 1 | 2016 | 783 | 0.030 |
Why?
|
Thyroid Gland | 1 | 2019 | 1170 | 0.030 |
Why?
|
Doxorubicin | 1 | 2019 | 2229 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2050 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2023 | 5306 | 0.020 |
Why?
|
Paclitaxel | 1 | 2019 | 1728 | 0.020 |
Why?
|
Genetic Loci | 1 | 2021 | 2631 | 0.020 |
Why?
|
Leiomyosarcoma | 1 | 2016 | 426 | 0.020 |
Why?
|
Risk | 1 | 2023 | 9602 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2018 | 1147 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2952 | 0.020 |
Why?
|
Menisci, Tibial | 1 | 2013 | 267 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 2979 | 0.020 |
Why?
|
Risk Factors | 1 | 2017 | 74889 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3552 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14653 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3610 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1982 | 0.020 |
Why?
|
Blood | 1 | 2012 | 598 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 1997 | 996 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2039 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4968 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7571 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9528 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2024 | 8623 | 0.020 |
Why?
|
Heart Arrest | 1 | 1997 | 1516 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 3043 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2017 | 2703 | 0.020 |
Why?
|
Arthroscopy | 1 | 2013 | 971 | 0.020 |
Why?
|
Animals | 3 | 2013 | 168939 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2022 | 20710 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3563 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8507 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4892 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2533 | 0.020 |
Why?
|
Oxygen | 1 | 2017 | 4252 | 0.020 |
Why?
|
Rabbits | 1 | 2011 | 4752 | 0.010 |
Why?
|
Cohort Studies | 2 | 2018 | 41706 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8540 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3360 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10580 | 0.010 |
Why?
|
Child, Preschool | 2 | 2023 | 42577 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15425 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 4860 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5990 | 0.010 |
Why?
|
Graft Survival | 1 | 2011 | 3904 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15912 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2012 | 4047 | 0.010 |
Why?
|
Adolescent | 3 | 2016 | 88902 | 0.010 |
Why?
|
Belgium | 1 | 1997 | 119 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2012 | 18986 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 1622 | 0.010 |
Why?
|
Rats | 1 | 2011 | 23717 | 0.010 |
Why?
|
Child | 2 | 2016 | 80670 | 0.010 |
Why?
|
United States | 1 | 2019 | 72945 | 0.010 |
Why?
|